| 26106 | OMSC1 | B2B CBC with Auto Differential | | HGMPS and AD: (White blood cell count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width, platelet, mean platelet volume, percent/absolute neutrophils, lymphocytes, monocytes, eosinophils, and basophils.)
Certain results and instrument flags will reflex peripheral smear review. Click on the link below to view slide review criteria.
| | 26105 | OMRUA | B2B Urine (Dipstick & Micro) | | STIX and Micro: (Color, Turbidity, Specific Gravity, pH, Protein, Glucose, Ketone, Bile, Blood, Urobilinogen, Esterase, and Nitrite, Casts, Renal Epithelial cells, WBC, RBC, Squamous cells, and Bacteria). | | 25525 | BABGSO | Babesia microti IgG Antibodies, Serum (BABG) | | | | 25230 | BABNAT | Babesia microti, Nucleic Acid Test | Babesia PCR, Babesiosis PCR | | | 22343 | BABE | Babesia Smear | Babesia microti, Giemsa Stain | | | 26138 | BRBPSSO | Bacteria PCR & Sequence (BRBPS) | 16S rRNA gene sequencing
Bacterial sequencing
Broad range
Broad-range
16S
Broad
Mycobacteria
Mycobacterial
Ribosomal RNA
rRNA
Sequencing
Next Generation Sequencing
NGS | If polymerase chain reaction (PCR) testing is negative, no sequencing is performed, and the test is resulted as negative. If PCR testing is positive, sequencing is performed. Strong positive results are first submitted to Sanger sequencing, which can yield results in as few as 4 days. Weak positive results, or Sanger sequencing results that are mixed, are submitted to next-generation sequencing (ie, targeted metagenomics testing). | | 26122 | CFRCSO | Bacterial Culture, Cystic Fibrosis with Antimicrobial Susceptibilities (CFRCS) | | | | 22345 | BAR | Barbiturates, Urine | Amobarbital, Amytal, Phenobarbital, Luminal, Nembutal, Pentobarbital. Secobarbital, Seconal, Solfoton , Phenobarbital, Butalbital, Fiorinal | | | 25091 | CO-BAR | Barbiturates, Urine, Confirm Only by GCMS | Amobarbital, Amytal, Phenobarbital, Luminal, Nembutal, Pentobarbital. Secobarbital, Seconal, Solfoton, Phenobarbital, Butalbital, Fiorinal | | | 25412 | BARTPAN | Bartonella Ab Panel, IgG & IgM (BART) | Bartonella henselae Abs, IgG/IgM; Bartonella quintana, IgG/IgM; Cat Scratch Disease, Bartonellosis, BART | | | 26208 | BCLLSO | B-Cell IGH Hypermutation Analysis (BCLL) | BCLL
IGVH
IGHV
Next Gen Sequencing Test
Somatic mutation (or Hypermutation)
CLL prognosis | | | 25628 | BLYMFSO | B-Cell Lymphoma Tissue, FISH (BLYM) | BLYM
BCL2 (18q21) rearrangement
BCL6 (3q27) rearrangement
Burkitt lymphoma
Burkitt-like lymphoma
CCND2
Diffuse Large Cell Lymphoma/"Double Hit"
Follicular lymphoma
Large BCL with IRF4 rearranged
MALT (18q21) rearrangement
MALT lymphoma
Mantle Cell Lymphoma (MCL)
MYC (8q24.1) rearrangement
MYC/Kappa
MYC/Lambda
Splenic Marginal Zone Lymphoma
t(11;14) (q13;q32) - CCND1/IGH
t(11;18) (q21;q21) - BIRC3/MALT1
t(14;18) (q32;q21) - IGH/MALT1
t(14;18)(q32;q21) - IGH/BCL2
t(2;8)(p12;q24) - IGK/MYC
t(8;14) (q24.1;q32) - MYC/IGH
t(8;22) (q24.1;q11.2) - MYC/IGL
IRF4
DUSP22
TNFRSF14
1p36 | This test does not include a pathology consultation. If a pathology consultation is desired, PATHC / Pathology Consultation should be ordered and the appropriate FISH test will be ordered and performed at an additional charge. Mayo Hematopathology Consultants are involved in both the preanalytic (tissue adequacy and probe selection, when applicable) and postanalytic (interpretation of FISH results in context of specific case, when applicable) phases. Depending on the lymphoma subtype suspected, the most appropriate probes to order are listed in the table: Common Chromosome Abnormalities in B-cell Lymphomas in Clinical Information. If the patient is being tracked for known abnormalities, indicate which probes should be used. A charge and CPT code is applied for each probe set hybridized, analyzed, and reported. Initial probe sets are run and completed within 4 days. If, based on testing algorithms, results of the initial probe sets require reflex testing, complete results will be available within 10 days. | | 25629 | BLPFSO | B-Cell Lymphoma, FISH Bld/BM (BLPF) | 17p- (17p deletion) or TP53
BCL2 (18q21) rearrangement
BCL6 (3q27) rearrangement
Burkitt Lymphoma
Burkitt-like Lymphoma
Diffuse Large Cell Lymphoma/"Double Hit"
Follicular Lymphoma
MALT (18q21) rearrangement
MALT Lymphoma
Mantle Cell Lymphoma (MCL)
MYC (8q24.1) rearrangement
MYC/Kappa
MYC/Lambda
Splenic Marginal Zone Lymphoma
t(11;14)(q13;q32) - CCND1/IGH
t(2;8)(p12;q24) - IGK/MYC
t(8;14)(q24.1;q32) - MYC/IGH
t(8;22)(q24.1;q11.2) - MYC/IGL
Extra-nodal Marginal Zone Lymphoma (ENMZL)
Triple hit lymphoma | This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred. When this test and flow cytometry testing for leukemia/lymphoma are ordered concurrently, the flow cytometry result will be utilized to determine if sufficient clonal B-cells are available for FISH testing. If the result does not identify a sufficient clonal B-cell population, this FISH test order will be canceled and no charges will be incurred. If FISH testing proceeds, probes will be performed based on the lymphoma subtype suspected/identified utilizing the table "Common Chromosome Abnormalities in B-cell Lymphomas" located in Clinical Information. If the patient is being tracked for known abnormalities, indicate which probes should be used. The following probe sets are available within this B-cell lymphoma FISH profile: -8q24.1 rearrangement, MYC -t(8;14), MYC/IGH -18q21 rearrangement, BCL2 -3q27 rearrangement, BCL6 -t(11;14), CCND1/IGH -17p deletion, TP53/D17Z1 -7q deletion, D7Z1/7q32 -18q21 rearrangement, MALT1 Marginal zone lymphoma (MZL) can be evaluated via probes for specific subtypes, as follows: mucosa-associated lymphoid tissue (MALT) lymphoma or extra-nodal marginal zone lymphoma (ENMZL) using the MALT1 rearrangement probe and splenic marginal zone lymphoma using probes for 7q deletion and 17p deletion. If no MZL subtype is provided, we will evaluate using probes for MALT1, 7q deletion and 17p deletion. | | 25401 | BCRAMSO | BCR/ABL, p210, RT-PCR(BCRAB) | Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
T lymphoblastic leukemia (T-ALL)
BCR-ABL1
BCR ABL
BCR/ABL
Chronic myelogenous leukemia (CML)
Philadelphia chromosome, Ph bone marrow/blood
t(9;22)
Tyrosine kinase inhibitor (TKI) therapy monitoring, PCR | | | 25411 | BCRADSO | BCR/ABL-1 RNA-Qual Diagnostic (BADX) | Philadelphia chromosome Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
BCR-ABL1
BCR ABL
BCR/ABL
B lymphoblastic leukemia (B-ALL)
Chronic myelogenous leukemia (CML)
Chronic myeloid leukemia
T lymphoblastic leukemia (T-ALL)
t(9;22) | This test is only qualitative and should not be used for routine monitoring (ie, quantitative mRNA level). Monitoring of most patients with chronic myeloid leukemia (CML) should be performed using BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies. Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies. | | 25546 | BC190SO | BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies (BA190) | Philadelphia chromosome, Ph bone marrow/blood
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
B lymphoblastic leukemia (B-ALL)
BCR ABL
BCR/ABL
BCR-ABL1
T lymphoblastic leukemia (T-ALL)
t(9;22) | | | 22346 | BENZ | Benzodiazepines, Urine | Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Lorazepam, Xanax, Librium, Valium, Ativan, Serax, Restoril, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol | The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present. | | 25092 | CO-BENZ | Benzodiazepines, Urine, Confirm Only by LCMS/MS | Clonazepam, Temazepam, Diazepam, Chlordiazepoxide, Alprazolam, Flunitrazepam, Flurazepam, Nordiazepam, Chlorazepate, Lorazepam, Xanax, Librium, Valium, Ativan, Serax, Restoril, Date Rape Drug, 7-Aminoflunitrazepam, Roofies, Rohypnol | | | 23169 | B2IGA | Beta 2 Glycoprotein 1 IgA | B2IgA, Beta 2 Glycoprotein
| | | 23168 | B2IGG | Beta 2 Glycoprotein 1 IgG | B2IgG, Beta 2 Glycoprotein | | | 23167 | B2IGM | Beta 2 Glycoprotein 1 IgM | B2IgM, Beta 2 Glycoprotein | | | 26319 | B2IGA | Beta 2 Glycoprotein 1, IgA | | | | 26320 | B2IGG | Beta 2 Glycoprotein 1, IgG | | | | 26321 | B2IGM | Beta 2 Glycoprotein 1, IgM | | | | 22347 | B2M | Beta-2 Microglobulin | B2M, B2MICRO | | | 22348 | B2MRUSO | Beta-2 Microglobulin, Urine (B2MU) | B2M, (Beta-2 Microglobulin) Urine; Beta 2 Microglobulin Test, Beta-2 Microglobulin, Urine | | | 24795 | B2TRNSO | Beta-2 Transferrin: Detection of Spinal Fluid in Other Body Fluid (BETA2) | B2 Transferrin; Cerebrospinal Fluid Leakage; CSF Specific Transferrin; CSF-Specific Transferrin; Otorrhea, Spinal Fluid;
Rhinorrhea, Spinal Fluid; Tau Protein; Transferrin B2; Transferrin, Spinal Fluid | | | 24970 | BCTXSO | Beta-Crosslaps (Beta-CTx), Serum (CTX) | B-CTx, Beta CrossLaps, Beta-CTx, C-Telopeptide, C-terminal collagen crosslinks, Carboxy terminal collagen crosslinks, CTx | | | 22242 | BOH | Beta-Hydroxybutyrate | Hydroxybutyrate, Ketones, 3-hydroxybutyrate | | | 22244 | CO2 | Bicarbonate | HCO3, CO2, Total CO2 | | | 24984 | BACIDSO | Bile Acids, Total Serum (BILEA) | Bile Salts Total | | | 22246 | BILE-U | Bile, Urine | Bilirubin, Urine | | | 22248 | DBIL | Bilirubin, Direct Only | DBIL, Conjugated Bilirubin, Fractionated Bilirubin | | | 22249 | NBILI | Bilirubin, Neonatal | NBili, Neonatal Bilirubin | Total Bilirubin, Direct Bilirubin
Indirect Bilirubin will be calculated | | 22250 | TBIL | Bilirubin, Total Only | TBil, Total Bilirubin | | | 22251 | TBIL-O | Bilirubin, Total, Other Body Fluids | Body Fluid Total Bilirubin | | | 23318 | BIOTESO | Bioavailable Testosterone, Total and Free (TTFB) | Androgens, Bioavailable Testosterone, NonSex Hormone Binding Globulin (SHBG), Testosterone Group, Testosterone, Total Only, Serum | Testosterone, Total Testosterone, Free Testosterone, Bioavailable | | 22252 | BIOTSSO | Biotinidase, Serum (BIOTS) | Biotin-amide amidohydrolase, Biotinidase deficiency, BTD | | | 24849 | QBKSO | BK Virus PCR, Qnt, Plasma (QBK) | BKV DNA
BKV Quantitative DNA
Polyomavirus
QBK
BK (Polyoma) Virus | | | 23421 | BKQNTSO | BK Virus PCR, Qnt, Urine (QBKU) | BK PCR Quant
BK Virus
BKV DNA
BKV Quantitative DNA
Polymavirus
QBK
BK (Polyoma) Virus | | | 26053 | LCBKPSO | BK Virus PCR, Qual, Plasma (LCBKP) | BK (Polyoma) Virus, BKV DNA, BKV Qualitative DNA, Polyomavirus | | | 23317 | BKVIRSO | BK Virus PCR, Qual, Urine (LCBK) | BK (polyoma) virus, BKV, BKV DNA, BKV Qualitative DNA, Polyomavirus | | | 22377 | BLASTO | Blastomyces Antibody | Blastomyces, antibody, serology | | | 26173 | BLCAGSO | Blastomyces Quantitative Antigen, CSF and BAL (316) | | | | 25016 | BLSAGSO | Blastomyces Quantitative Antigen, Serum (316) | Blastomyces Dermatitidis QNT AG | | | 25581 | BLUAGSO | Blastomyces Quantitative Antigen, Urine (316) | Blastomyces Dermatitidis QNT AG | | | 26100 | CHR2NIC | BLIPO, Glucose and Nicotine | Concert Health, CHR | Includes GLU, BLIPO (Total Cholesterol, HDL Cholesterol, Triglyceride, calculated LDL cholesterol and NONHDL Cholesterol), and NICTS (Nicotine and Metabolites). | | 22256 | ABGH | Blood Gases and Hemoglobin, Arterial | Art. Blood Gas w/Hgb | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) and Hemoglobin results. | | 22257 | VBGH | Blood Gases and Hemoglobin, Venous | Venous Bld Gases w/Hgb | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only), and Hemoglobin | | 22258 | ABGL | Blood Gases and NA/K/IC, Arterial | Blood Gas, Art. w/ Sodium, Potassium, Ionized Calcium | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) and Sodium, Potassium, and Ionized Calcium | | 22259 | CBGL | Blood Gases and Na/K/Ic, Capillary | Blood Gas, Cap. w/ Sodium, Potassium, Ionized Calcium | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation), Sodium, Potassium, and Ionized calcium | | 22260 | VBGL | Blood Gases and Na/K/Ic, Venous | Ven.Bld.Gases & Na/K/Ion.Ca | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only), Sodium, Potassium, and Ionized calcium | | 22261 | ABG | Blood Gases, Arterial | Art.Blood Gas, ABG, PCO2, PO2 | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) | | 22262 | CBG | Blood Gases, Capillary | CBG, Capillary Blood Gases | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) | | 22265 | VBGNAK | Blood Gases, Na/K, Venous | Venous Bld, Gases & Na/K | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only), Sodium, and Potassium | | 22264 | VBGLH | Blood Gases, Na/K/Ic and Hemoglobin, Venous | Ven.Bld.Gases & Na/K/Ion.Ca w/Hgb | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation calculated HCO3-Marshfield Only), Sodium, Potassium, Ionized calcium, and Hemoglobin | | 22263 | ABGLH | Blood Gases, NA/K/IC, AND Hemoglobin, Arterial | Blood gas with Hgb, Sodium, Potassium and Ionized Calcium | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, bicarbonate HCO3, base excess BE, O2 Saturation) and Sodium, Potassium, Ionized Calcium, and Hemoglobin results. | | 22266 | UABG | Blood Gases, Umbilical Cord Arterial | Cord Gas, Arterial | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE) | | 22267 | UVBG | Blood Gases, Umbilical Cord Venous | Cord Gas, Venous | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE) | | 22268 | VBG | Blood Gases, Venous | Venous Blood Gases, VBG | Panel includes Blood Gas (pH, partial pressure of carbon dioxide pCO2, partial pressure of oxygen pO2, base excess BE, O2 Saturation, calculated HCO3-Marshfield Only) | | 22269 | ABO/RH | Blood Typing, ABO and RH | ABO Grouping, ABO/RH, Type and Rh, ABO/RH Typing, BB - Blood Type, ABO & Rh | | | 25028 | BALLFSO | B-Lymphoblastic Leukemia/Lymphoma, FISH (BALLF) | +4,+10,+17
17p- (17p deletion) or TP53
9p- (9p deletion) or CDKN2A or p16
Hyperdiploidy
IGH (14q32) rearrangement
t(1;19)(q23;p13.3) - PBX1/TCF3
t(11;19)(q23;p13.1) - MLL/ELL
t(11;19)(q23;p13.3) - MLL/MLLT1 or MLL/ENL
t(12;21)(p13;q22) - TEL/AML1 or ETV6/RUNX1
t(4;11)(q21;q23) - AFF1/MLL or AF4/MLL
t(9;11)(p22;q23) - MLLT3/MLL or AF9/MLL
t(9;22)9q34;q11.2) - BCR/ABL1
t(X;14)(p22.3;q32) - CRLF2/IGH
t(Y;14)(p11.32;q32) - CRLF2/IGH
t(6;11)(q27;q23) - MLLT4/MLL or AF6/MLL
t(10;11)(p12;q23) - MLLT10/MLL or AF10/MLL
MLL or KMT2A (11q23) rearrangement
MYC (8q24.1) rearrangement
ABL2 (1q25) rearrangement
PDGFRB (5q33) rearrangement
JAK2 (9p24.1) rearrangement
ABL1 (9q34) rearrangement
CRLF2 (Xp22.33) or (Yp11.32) rearrangement
P2RY8 (Xp22.33) or (Yp11.32) rearrangement
Ph-like ALL
BCR-ABL1 like ALL
iAMP21
Hypodiploidy/pseudo-hyperdiploid
Hyporiploid/Near-Triploid
Philadelphia-like ALL |
This B-cell acute lymphoblastic leukemia (B-ALL) fluorescence in situ hybridization (FISH) test may be ordered in 4 distinct ways allowing different combinations of probes to be utilized based on the clinical question. The 4 ways this B-ALL FISH test can be ordered are as follows: -Standard (diagnostic) B-ALL FISH panel -Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) panel -Combined-Standard (diagnostic) B-ALL FISH panel + Ph-like ALL panel -Individual B-ALL FISH probes (per client request) The specific B-ALL FISH panel or FISH probes requested must be noted on the request form or in the reason for referral. If no specific panel or FISH probe request is indicated, the "Standard (diagnostic) B-ALL FISH panel" will be performed. The Standard (diagnostic) B-ALL FISH panel includes testing for the following abnormalities, using the FISH probes listed: Hyperdiploidy, +4,+10,+17: D4Z1/D10Z1/D17Z1 t(12;21)(p13;q22), ETV6/RUNX1 fusion, ETV6/RUNX1 D-FISH iAMP21, RUNX1 amplification, ETV6/RUNX1 D-FISH t(9;22)(q34;q11.2), BCR/ABL1 fusion, BCR/ABL1 D-FISH t(1;19)(q23;p13), PBX1/TCF3 fusion, PBX1/TCF3 D-FISH t(11q23;var), MLL (KMT2A) rearrangement, MLL (KMT2A) break-apart del(9p), CDKN2A deletions, CDKN2A/D9Z1 t(14q32;var), IGH rearrangement, IGH break-apart del(17p), TP53 deletions, TP53/D17Z1 8q24.1 rearrangement, MYC break-apart t(Xp22.33;var) or t(Yp11.32;var), P2RY8 rearrangement, P2RY8 break-apart t(Xp22.33;var) or t(Yp11.32;var), CRLF2 rearrangement, CRLF2 break-apart -When an MLL (KMT2A) rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(4;11)(q21;q23) AFF1/MLL, t(6;11)(q27;q23) MLLT4/MLL, t(9;11)(p22;q23) MLLT3/MLL, t(10;11)(p13;q23) MLLT10/MLL, t(11;19)(q23;p13.1) MLL/ELL, or t(11;19)(q23;p13.3) MLL/MLLT1. -When an IGH and/or CRLF2 rearrangement is identified, reflex testing will be performed using the CRLF2/IGH fusion probe set to identify a potential t(X;14)(p22.33;q32) or t(Y;14) (p11.32;q32) "cryptic translocation." -When an extra signal of ABL1 is identified in BCR/ABL1 testing, reflex testing will be performed using the ABL1 break-apart probe set to identify the presence or absence of an ABL1 rearrangement. -If a MYC rearrangement is identified, break-apart probe sets for BCL2 and BCL6 will be performed. *The "Standard (diagnostic) B-ALL FISH panel" will be automatically reflexed to the Philadelphia Ph-like ALL panel on pediatric and young adult patients (age <30) who demonstrate normal or nonclassical abnormalities on the Standard (diagnostic) panel. In other circumstances, the Ph-like ALL panel may be recommended and the client notified before performing this testing. The Ph-like ALL panel includes testing for the following abnormalities using the FISH probes listed: -t(1q25;var), ABL2 rearrangement, ABL2 break-apart -t(5q33;var), PDGFRB rearrangement, PDGFRB break-apart -t(9p24.1;var), JAK2 rearrangement, JAK2 break-apart -t(9q34;var), ABL1 rearrangement, ABL1 break-apart -t(Xp22.33;var) or t(Yp11.32;var), P2RY8 rearrangement, P2RY8 break-apart -t(Xp22.33;var) or t(Yp11.32;var), CRLF2 rearrangement, CRLF2 break-apart -monosomy 7 or del(7p), IKZF1 deletions, IKZF1/CEN7 enumeration -When a PDGFRB rearrangement is identified, reflex testing may be performed using the PDGFRB/ETV6 fusion probe set to identify a potential t(5;12)(q33;p13) translocation. -When a CRLF2 rearrangement is identified, reflex testing will be performed using the CRLF2/IGH fusion probe set to identify a potential t(X;14)(p22.33;q32) or t(Y;14) (p11.32;q32) "cryptic translocation." -If an ABL1 rearrangement is identified, reflex testing will be performed using the BCR/ABL1 dual-color, double fusion FISH probe set to evaluate for the presence or absence of BCR/ABL1 fusion. We recommend the following testing algorithm for patients with B-acute lymphoblastic leukemia (B-ALL): -At diagnosis, standard (diagnostic) B-ALL FISH panel and/or conventional chromosome studies (CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow) should be performed. If there is limited specimen available for CHRBM, this test will be performed instead. -If the patient clinically relapses, a conventional chromosome study is useful to identify cytogenetic changes in the neoplastic clone or the possible emergence of a new therapy-related myeloid clone. This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred. If this test is ordered and the laboratory is informed that the patient is on a COG protocol, this test will be canceled and automatically reordered by the laboratory as COGBF / B-Lymphoblastic Leukemia/Lymphoma, Children's Oncology Group Enrollment Testing, FISH, Varies. | | 25460 | BFCC | Body Fluid Cell Count | Cell Count Body Fluid, BF Cell Ct | Total Nucleated Cell Count (WBC), Red Blood Cell Count | | 22415 | BFCC/D | Body Fluid Cell Count and Manual Differential (Not CSF) | Cell Count and Differential, Body Fluid, BFD Cell Ct + Diff | Total Nucleated Cell Count (WBC), Red Blood Cell Count, Percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils and any abnormal nucleated cells present including blasts and nucleated red blood cells. | | 25463 | BAP | Bone Alkaline Phosphatase | Bone-specific Alkaline phosphatase, Ostase | | | 22381 | B.M. | Bone Marrow Differential | Bone Marrow Biopsy, Bone Marrow Aspirate, Bone Marrow Exam | | | 23165 | BORDPCR | Bordetella by PCR | Pertussis PCR, Whooping Cough by PCR, Parapertussis PCR | | | 25561 | BRAFTSO | BRAF Mutation Analysis (V600E), Tumor (BRAFT) | V600E, BRAF | BRAF Mutation Analysis, Slide Review | | 25560 | BRAFDSO | BRAF V600E/V600K Somatic Mutation Analysis, Tumor (BRAFD) | Anaplastic thyroid carcinoma
BRAF
BRAF mutation
BRAFD
Brain cancer
Circulating tumor cells
Circulating tumor DNA
CNS tumor
Colon cancer
Colorectal cancer
Craniopharyngioma
Erdheim-Chester disease
Glioma
Hairy Cell leukemia
Histiocytic lesion
Liquid biopsy
Lung cancer
Melanoma
Papillary thyroid carcinoma
V600E
V600K | Slide review, BRAF Mutation Analysis | | 23094 | CA2729 | Breast Cancer Antigen (CA 27.29) | Biomira Truquant BR, Breast Cancer Tumor Markers, Breast Carcinoma, Cancer Antigen 27.29 , (CA 27.29), MAM 6, Milk Mucin, CA 27-29 | | | 22383 | BCA | Breast Cancer Antigen 15-3 | Breast Ca Ag 15-3 (BCA) | | | 22384 | BRUCSO | Brucella Abortus Serology (SS02002) | Brucellosis, Undulant fever, B. abortus, Brucellosis Agglutinins | Quantitative direct agglutination procedure for the detection of antibody to B. abortus, B. melitensis, and B. suis.
Antibodies to Brucella canis, a rare cause of brucellosis, are not detected by this method. | | 23109 | BNP | B-Type Natriuretic Peptide | BNP, Brain-type Natriuretic peptide | | | 26078 | BPSO | Bullous Pemphigoid, BP180 & BP230, IgG Antibodies, Serum (BPAB) | BP 180 BP 230 Bullous Pemphigoid | | | 25152 | BUP | Buprenorphine, Urine | Buprenex, Suboxone, Subutex, Temgesic | | | 25374 | CO-BUP | Buprenorphine, Urine, Confirm Only by LCMS | Buprenex, Suboxone, Subutex, Temgesic | | | 24755 | BUPSC | Buprenorphine, Urine, Qual | Buprenex, Suboxone, Subutex, Temgesic | | | 23249 | BUPRSO | Bupropion, Serum (178) | | |
|